Kynos Builds Out Senior Management Team with Appointment of Dr Alison Strutt, a Seasoned Biotech and ex-GSK Executive, as CFO

  • Dr Alison Strutt joins Kynos senior management team as CFO
  • Brings extensive strategic, transactional, and operational experience in biotech and large pharma to the Kynos leadership team


Edinburgh, UK – 23 June 2022 – Kynos Therapeutics Ltd (Kynos or the Company), an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology today announced the appointment of Dr Alison Strutt as Chief Finance Officer (CFO).

Alison Strutt is a seasoned healthcare finance executive with extensive strategic, transactional and operational experience. She will combine her current role as Chief Operating Officer at NodThera Inc.  whilst supporting Kynos Therapeutics as CFO. She formerly held a number of senior finance roles at GSK, including as Chief of Staff to the Chief Finance Officer, where she was responsible for transforming GSK’s financial reporting processes and organisation as well as leading local completions of the global Novartis transaction. Alison also served as CFO of GSK’s drug discovery group, where she established the Tres Cantos Open Lab and Catalyst Science Park at GSK’s UK flagship R&D site. Prior to time at GSK, Alison led the UK M&A life sciences team at Deloitte in London. She holds a Ph.D. in chemistry and physical chemistry from the University of Wales, Cardiff and is a Fellow of the Institute of Chartered Accountants for England and Wales.

Welcoming Alison to the company, CEO of Kynos Therapeutics, Damian Mole said, “Alison is an exceptional addition to the Kynos leadership team, and we are delighted to have been able to attract her to the Company. Kynos is rapidly building momentum towards the clinic, and Alison’s experience across large pharma and biotech covers finance at the operational level as well as a strategic outlook. This breadth of skill and experience will support Kynos to achieve the strong position that we are aiming for in the near future.”

Alison Strutt, CFO of Kynos Therapeutics, said, “I am very excited to be getting involved in Kynos at this critical point in its journey, and I am really looking forward to working with the leadership team and the Board to help create a leading company in immunometabolic medicine.”

About Kynos Therapeutics –

Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. It is a spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism. Its innovative pipeline of first-in-class KMO inhibitors across key indications in inflammation, immunity and metabolism, was originally co-developed through a collaboration between GSK and the University of Edinburgh and is now exclusively licensed to Kynos.

Based in Edinburgh, UK, the company is financed by equity investment from Epidarex Capital, IP Group plc and Scottish Enterprise as well as a grant from Innovate UK.

Follow us on LinkedIn and Twitter